Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05731726
Other study ID # ASTRUM-REC01
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date February 22, 2023
Est. completion date February 20, 2025

Study information

Verified date March 2023
Source Zhejiang University
Contact Kefeng Ding, doctor
Phone +86 13588425440
Email dingkefeng@zju.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Colorectal cancer of Mismatch Repair-proficient (pMMR)/ Microsatellite Stability (MSS) accounts for approximately 85% of all colorectal cancer patients, which might be insensitive to immunotherapy. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy, such as CAPEOX regimen, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Celecoxib, a COX-2 inhibitor, can improve the immune microenvironment and have a potential to synergy with immunotherapy. Chemotherapy can improve the immunogenicity of cancer cells that might enhance the efficacy of immunotherapy. The aim of this study is to explore whether chemotherapy and cyclooxygenase (COX) inhibitors combined with anti-PD-1 monoclonal antibody (mAb) could improve efficacy for resectable colorectal cancer patient with the pMMR/MSS phenotype.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date February 20, 2025
Est. primary completion date February 20, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Willing and able to provide written informed consent. 2. Male or female subjects ? 18 years ? 75 of age. 3. Histological or cytological documentation of adenocarcinoma of the rectum. 4. No previous any systemic anticancer therapy for rectal cancer disease. 5. The lower margin of the tumor is less than 10cm from the anus verge. 6. cT3N1M0, T4N0-1M0 MSS. 7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 8. At least one measurable lesion was evaluated according to RECIST 1.1. 9. Eligible tumor tissues were identified for MSI/MMR assays. 10. Expected survival of at least 3 months. 11. Hepatitis B Surface Antigen (HBsAg) (-) and Hepatitis B Core Antibody (HBcAb) (-). If HBsAg (+) or HBcAb (+), HBV-DNA must be less than 2500 copies/mL or 500 IU/mL to be enrolled. 12. Patients with HCV antibody (-) or HCV-RNA negative can be enrolled. Aspartate aminotransferase (AST) must be = 3 x ULN for the lab. If HCV-RNA is positive, patients with both alanine aminotransferase (ALT) and aspartate aminotransferase (AST) performed =3×ULN could be enrolled. Patients infected with both hepatitis B virus and hepatitis C virus should be excluded (positive for HBsAg or HBcAb and positive for HCV antibodies). Exclusion Criteria: 1. Patients with recurrent rectal cancer or a history of pelvic radiotherapy. 2. Patients with a history of inflammatory bowel disease. 3. Patients with acquired immunodeficiency syndrome (AIDS-related illnesses) or known human immunodeficiency virus (HIV) disease (HIV1 antibody, HIV2 antibody, HTLV1 antibody positive) should be excluded. 4. Patients who are preparing for or have previously received an organ or bone marrow transplant. 5. History of myocardial infarction, poorly controlled arrhythmias (including QTc interval =470 ms in women) in the 6 months prior to randomization (QTc interval calculated by Fridericia formula). 6. According to New York College of Cardiology (NYHA) standards for Grade III-IV cardiac insufficiency or cardiac color ultrasound: left ventricular ejection fraction (LVEF) <50%.Poor hypertension control (systolic blood pressure =150 mmHg and/or diastolic blood pressure =100 mmHg), a past hypertensive crisis or hypertensive encephalopathy. Patients with active tuberculosis. 7. The patients had previously been treated with other antibodies/drugs that target immune checkpoints, such as PD-1, PD-L1, and cytotoxic T lymphocyte-associated Antigen 4 (CTLA-4). 8. Patients are participating in other clinical studies, or plan to start this study treatment less than 14 days from the end of the previous clinical study. 9. Uncontrolled tumor-related pain. 11.A known history of severe allergy to any monoclonal antibody. 12.Known to be allergic to any oxaliplatin and capecitabine ingredients. 13.Pregnant or lactating women. 14.The investigators determined that the patient had other factors that might have led to the early termination of the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Serplilumab
Serplilumab is an innovative monoclonal antibody targeting PD-1, developed by Shanghai Henlius Biotech, Inc. 300 mg, q3w
Capecitabine
Given PO
Oxaliplatin
Given IV
Celecoxib
celebrex

Locations

Country Name City State
China Second Affiliated Hospital School of Medicine Zhejiang University Hangzhou Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
Zhejiang University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pathological complete response rates Proportion of patients experiencing a pCR to perioperative PD-1 antibody 1 year
Secondary Major pathological response rates The proportion of patients experiencing a major pathological response to perioperative PD-1 antibody 1 year
Secondary Rate of clinical complete response rate (cCR) Proportion of patients experiencing a cCR to perioperative PD-1 antibody 1 year
Secondary R0 resection rates The proportion of patients achieved a complete resection with negative margin 1 year
Secondary Treatment-related adverse events. Assessed by evaluation of treatment-related adverse events. 1 year
Secondary Detection of MRD To detect ctDNA in peripheral blood before and after treatment 1year
Secondary single cell sequence Use single cell sequence to describe changes in the microenvironment of rectal cancer before and after treatment 1year
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05920928 - Comparison of the Clinical Response of Total Neoadjuvant Treatment of Two Methods of Long-term or Short-term Chemoradiotherapy in Rectal Cancer N/A
Completed NCT06314737 - Assessment of Efficacy of Neoadjuvant Therapy in Locally Advanced Rectal Cancer
Recruiting NCT05524012 - Longitudinal Multimodal Response Assessment During Neoadjuvant Treatment of Rectal Cancer
Recruiting NCT05601505 - Circulating Tumor DNA-guided Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer Phase 2
Recruiting NCT05876026 - MRI T1 Relaxation Time in Rectal Cancer
Completed NCT05622357 - Prospective Study of Short Course Radiation Therapy Followed by Neoadjuvant Chemotherapy and Surgery in Locally Advanced Rectal Cancer Phase 2
Terminated NCT04406857 - Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy Treatment (Capecitabine) During Radiation Therapy for Rectal Cancer Phase 1
Not yet recruiting NCT06276686 - Exercise for Improving Long-course Chemoradiotherapy Efficacy in People With Locally Advanced Rectal Cancer N/A
Not yet recruiting NCT06292975 - Exercise for Improving Radiotherapy Efficacy in Rectal Cancer N/A
Recruiting NCT05591534 - Endorectal Brachytherapy for Rectal Cancer Phase 2
Recruiting NCT05722288 - Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers Phase 2
Not yet recruiting NCT05645094 - Neoadjuvant Envafolimab in Resectable and Locally Advanced MSI-H/dMMR Rectal Cancer
Active, not recruiting NCT06314750 - Deep Learning Based MRI Radiomics in Predicting the Clinical Risk of Locally Advanced Rectal Cancer
Recruiting NCT06312982 - A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer: From a Multicenter Phase II Cohort to a Phase III Randomized Controlled Study Phase 2/Phase 3
Recruiting NCT04703101 - Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer Phase 1
Recruiting NCT05610163 - Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation Phase 2
Recruiting NCT05245786 - An Investigational Scan (64Cu-Labeled M5A Antibody) in Combination With SOC Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer Early Phase 1
Terminated NCT03280277 - Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Locally Advanced Rectal Cancer Early Phase 1
Recruiting NCT05772923 - Organ Preservation in Rectal Cancer: Contact X-ray Brachytherapy vs Extending the Waiting Interval and Local Excision N/A
Recruiting NCT05792735 - Neoadjuvant Cadonilimab Plus Chemotherapy Following Short-Course Radiotherapy in Locally Advanced Rectal Cancer Phase 2